[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-331524-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-331524-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","pan-cancer-landscape-analysis-of-nop58-and-its-oncogenic-driving-role-in-lung-adenocarcinoma","Pan-cancer landscape analysis of NOP58 and its oncogenic driving role in lung adenocarcinoma","","Lung adenocarcinoma (LUAD) continues to have poor outcomes despite recent therapeutic progress. This study clarifies the role of the NOP58 ribonucleoprotein across cancers and confirms its oncogenic relevance in LUAD using bioinformatics and functional experiments in vitro and in vivo. NOP58 is overexpressed in multiple tumor types and shows strong performance for predicting 20 cancer types via ROC analysis, with links to prognosis in specific cancers. In LUAD, NOP58 correlates with TNM and pathologic stage, smoking status, and clinical effectiveness endpoints, associates with Th2 infiltration, and negatively relates to cytotoxic and Th1 immune signals. Inhibiting NOP58 reduces LUAD proliferation, migration, invasion, and xenograft tumor growth, while tissue microarrays show higher NOP58 in tumors than adjacent normal tissue. NOP58 is proposed as a diagnostic/prognostic biomarker and independent prognostic risk factor for LUAD.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/pan-cancer-landscape-analysis-of-nop58-and-its-oncogenic-driving-role-in-lung-adenocarcinoma/331524/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/pan-cancer-landscape-analysis-of-nop58-and-its-oncogenic-driving-role-in-lung-adenocarcinoma/331524.png","ImageObject",300,407,{"name":42,"@type":43},"Quinn","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-05","2026-09-21",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",7,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What is the overall purpose of this study on NOP58 in LUAD?","Question",{"text":63,"@type":64},"To elucidate NOP58’s potential role across cancers and validate its oncogenic significance specifically in lung adenocarcinoma using bioinformatics and functional assays.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How does NOP58 expression relate to clinical and immune features in LUAD?",{"text":68,"@type":64},"NOP58 expression is associated with TNM stage, pathologic stage, smoking status, and clinical effectiveness endpoints, and it correlates with Th2 infiltration while negatively relating to other immune cells such as CD8 T and cytotoxic/Th1-related signals.",{"name":70,"@type":61,"acceptedAnswer":71},"What experimental results support NOP58 as a functional oncogenic driver in LUAD?",{"text":72,"@type":64},"NOP58 inhibition in LUAD cells reduces proliferation, migration, and invasion, and NOP58 knockdown suppresses tumor growth in mouse xenograft models, with tumor tissue showing higher NOP58 than adjacent normal tissue.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},331524,1790196634,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},"Healthcare",40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},8,30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":111,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":108,"preview_page_count":4},962075114765,"https://ap-avatar.wpscdn.com/davatar_a8503ba1806abce46bf441b54a3ca4cd","[www. nature.com/scientificreports](www. nature.com/scientificreports)  \nOPEN  \nPan-cancer landscape analysis of NOP58 and its oncogenic driving role in lung adenocarcinoma  \nShushu Qian1,4, Huafeng Liu2,4, Min Zhang3, Li Zhang1, Yunlan Dai1, Xiangming Ye1, Wanshun Wen1􀀍 & Ruidong Cheng1􀀍  \nDespite improvements in treatment in recent years, patients with lung adenocarcinoma (LUAD) still face poor prognoses. In this study, we elucidated the potential role of NOP58 ribonucleoprotein in pan-cancer and validated its oncogenic significance in LUAD using bioinformatics and in vitro and in vivo functional assays. NOP58 was found to be overexpressed in various types of tumors. It had great precision for predicting 20 distinct cancer types using receiver operating characteristic curve (ROC) as well as significant connections with the prognoses in particular cancers. In LUAD, NOP58 expression was correlated substantially with the TNM stage, pathologic stage, smoking status, and effectiveness endpoints, when we analyzed its association with clinical characteristics in LUAD. Elevated NOP58 expression was shown as connected with Th2 cell infiltration while also negatively linked with infiltrating other immune cells, such as CD8 T, cytotoxic, and Th1. By inhibiting NOP58 within the LUAD cells, we found a decrease in cells’ capability to proliferate, migrate, and invade. Knockdown of NOP58 inhibited tumor growth in mouse xenograft models. Furthermore, the tissue microarray study indicated that there was a greater expression of NOP58 in the tumor tissues compared to adjacent normal tissues in LUAD. Our findings revealed that NOP58 could be an outstanding bio-index for pancancer diagnosis and prognosis and an independent prognostic risk factor in LUAD.  \nKeywords NOP58 ribonucleoprotein, Lung adenocarcinoma, Pan-cancer, Prognosis, Immune infiltrate  \nThe incidence and mortality rate of lung cancer are the highest of all cancers worldwide. With 2.09 million deaths annually, lung cancer results continue to remain dismal1. Lung cancer might be separated into small-and nonsmall cell lung cancer (NSCLC)2. Lung adenocarcinoma (LUAD) is the most prevalent subtype of NSCLC3, with 50% of all lung cancer diagnoses, and its prevalence has been increasing2,4. New treatments for LUAD, including targeted therapy and immunotherapy, have been developed recently4. However, very few individuals suffering from LUAD benefit from these therapies. Cancers continue to change and acquire resistance mechanisms to escape treatment. The need for more effective biomarkers to facilitate novel therapeutics is therefore essential.  \nThe NOP58 ribonucleoprotein is a protein-coding gene located on chromosome 2 that is also known as NOP5, HSPC120, and NOP5/NOP585. This gene encodes a protein of 59.6 kDa molecular weight that is mostly localized in the nucleolus5. NOP58 produces tiny nucleolar ribonucleoprotein complexes with short nucleolar RNAs and facilitates post-transcriptional alterations, pseudouridylation, methylation, and cleavage for rRNA maturation as a nucleolar protein6. NOP58, NOP56, and 15.5 kDa are necessary for carcinogenesis, snoRNA development, stability, and localization7. Overexpression of NOP58 is inversely linked with overall survival (OS) in hepatocellular carcinoma (HCC) individuals and might be a viable bio-index for predicting HCC prognosis8. And it might also contribute to LUAD recurrence9. A study has shown that long noncoding RNA (lncRNA) ZFAS1 could promote small nucleolar RNA-stimulated 2’-O-methylation through recruiting NOP58 in colorectal cancer10. PGM5P3-AS1 reduced the development of triple negative breast cancer (TNBC) by enlisting NOP58 to stabilize the mRNA for MAP1LC3C11. Additionally, another study has shown that NOP58 might enhance the stability of FAM83A mRNA and contribute to the advancement of hepatocellular carcinoma12. Despite NOP58’s molecular actions being observed in these studies, its role in LUAD is not well understood. In th","cbCairrcEJWXM5Ca","https://ap.wps.com/l/cbCairrcEJWXM5Ca","pdf",12349623,16,"English","# Pan-cancer landscape analysis of NOP58 and its oncogenic driving role in lung adenocarcinoma\n## NOP58 Expression patterns in pan-cancer","[{\"question\":\"What is the overall purpose of this study on NOP58 in LUAD?\",\"answer\":\"To elucidate NOP58’s potential role across cancers and validate its oncogenic significance specifically in lung adenocarcinoma using bioinformatics and functional assays.\"},{\"question\":\"How does NOP58 expression relate to clinical and immune features in LUAD?\",\"answer\":\"NOP58 expression is associated with TNM stage, pathologic stage, smoking status, and clinical effectiveness endpoints, and it correlates with Th2 infiltration while negatively relating to other immune cells such as CD8 T and cytotoxic/Th1-related signals.\"},{\"question\":\"What experimental results support NOP58 as a functional oncogenic driver in LUAD?\",\"answer\":\"NOP58 inhibition in LUAD cells reduces proliferation, migration, and invasion, and NOP58 knockdown suppresses tumor growth in mouse xenograft models, with tumor tissue showing higher NOP58 than adjacent normal tissue.\"}]","Pan-cancer landscape analysis of NOP58 and its oncogenic driving role in lung adenocarcinoma | PDF",1789993726]